WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 10, 90-95. Review Article ISSN 2277–7105

CANCER: MOLECULAR PATHOPHYSIOLOGY, DIAGNOSIS, AND EMERGING THERAPEUTIC STRATEGIES – A REVIEW

***Isha Sharma**

Assistant Professor, Rayat Institute of Pharmacy, Railmajra, Punjab, India.

Article Received on 16 April 2026,
Article Revised on 06 May 2026,
Article Published on 16 May 2026,

https://doi.org/10.5281/zenodo.20196996

***Corresponding Author**
Isha Sharma
Assistant Professor, Rayat Institute of Pharmacy, Railmajra, Punjab, India.

How to cite this Article: *Isha Sharma. (2026). Cancer: Molecular Pathophysiology, Diagnosis, And Emerging Therapeutic Strategies – A Review. World Journal of Pharmaceutical Research, 15(10), 90–95.

ABSTRACT

Cancer is a multifactorial disease characterized by uncontrolled cell proliferation, resistance to apoptosis, and the ability to invade surrounding tissues and metastasize to distant organs. It remains one of the leading causes of mortality worldwide. The pathogenesis of cancer involves complex interactions between genetic mutations, environmental exposures, and lifestyle-related factors. Recent advances in molecular biology have significantly enhanced the understanding of cancer mechanisms, leading to the development of innovative diagnostic and therapeutic strategies. This review provides a comprehensive overview of cancer pathophysiology, major risk factors, classification, diagnostic approaches, and both current and emerging treatment modalities. Special emphasis is placed on targeted therapy, immunotherapy, and precision medicine as promising approaches for improved cancer management.

KEYWORDS: Cancer, Metastasis, Oncology, Targeted Therapy, Immunotherapy, Precision Medicine, Carcinogenesis, Diagnosis.

1. INTRODUCTION

Cancer is a group of diseases characterized by abnormal and uncontrolled cell growth with the ability to invade and spread to other parts of the body. It represents a major global health burden, with increasing incidence and mortality rates. The transformation of normal cells into malignant cells is a multistep process involving genetic and epigenetic alterations that disrupt normal cellular homeostasis.

Advancements in cancer research have improved early detection and treatment outcomes; however, challenges such as late diagnosis and therapeutic resistance continue to limit effective management.

According to global reports, cancer incidence continues to rise, highlighting the urgent need for improved diagnostic and therapeutic strategies.

2. Molecular Pathophysiology of Cancer

Cancer arises from the accumulation of genetic and epigenetic alterations affecting genes that regulate cell growth, differentiation, and apoptosis. Alterations in these genes lead to loss of growth control and provide survival advantages to abnormal cells.

Cancer cells exhibit hallmark biological characteristics such as sustained proliferation, evasion of apoptosis, induction of angiogenesis, and the ability to metastasize. Metastasis is a complex multistep process involving local invasion, entry into circulation, survival in the bloodstream, and colonization of distant organs.



Figure 1: Major mechanisms involved in cancer development, including genetic mutations, angiogenesis, and metastasis. (Source: Author-created).

3. Risk Factors

The development of cancer is influenced by multiple factors:

3.1 Lifestyle Factors

Smoking, alcohol consumption, poor diet, obesity, and physical inactivity are major contributors to cancer risk.

3.2 Environmental Factors

Exposure to radiation, environmental pollutants, and industrial carcinogens increases the likelihood of cancer development.

3.3 Genetic Factors

Inherited mutations, such as BRCA gene mutations, significantly increase the risk of certain cancers.

3.4 Infectious Agents

Viruses such as human papillomavirus (HPV) and hepatitis B and C viruses are strongly associated with cancer development.

4. Classification of Cancer

Cancer is classified based on tissue of origin:

- **Carcinomas** – arise from epithelial cells
- **Sarcomas** – originate from connective tissues
- **Leukemias** – cancers of blood-forming tissues
- **Lymphomas** – cancers of the lymphatic system
- **Myelomas** – cancers of plasma cells

5. Diagnosis of Cancer

Accurate diagnosis is essential for effective treatment. Common diagnostic methods include:

- Imaging techniques (CT scan, MRI)
- Histopathological examination (biopsy)
- Tumor markers
- Molecular diagnostics
- Liquid biopsy, a non-invasive and emerging technique, provides an important tool for early cancer detection, prognosis, and treatment monitoring.

6. Treatment Strategies

6.1 Chemotherapy

- Involves the use of cytotoxic drugs to destroy rapidly dividing cancer cells.

6.2 Radiation Therapy

- Uses high-energy radiation to kill or damage cancer cells.

6.3 Surgery

- Effective for the removal of localized tumors.

6.4 Targeted Therapy

- Focuses on specific molecular targets involved in tumor growth and progression.

6.5 Immunotherapy

- Enhances the body's immune system to recognize and destroy cancer cells.

6.6 Hormonal Therapy

- Used in hormone-dependent cancers such as breast and prostate cancers.



Figure 2: Mechanisms of different cancer treatment strategies, including chemotherapy, radiation therapy, targeted therapy, and immunotherapy. (Source: Author-created).

7. Emerging Therapeutic Advances

Recent innovations in cancer treatment include:

- Precision medicine
- Gene therapy
- Nanotechnology-based drug delivery
- Artificial intelligence in oncology

These approaches aim to improve treatment efficacy while minimizing adverse effects, and these emerging approaches are transforming cancer treatment by enabling personalized and more precise therapeutic interventions.

8. Challenges in Cancer Management

Despite advancements, several challenges remain:

- Drug resistance
- High cost of treatment
- Late diagnosis
- Limited healthcare accessibility

9. CONCLUSION

Cancer remains a major global health concern. Advances in molecular biology and therapeutic strategies have improved patient outcomes; however, further research is required to overcome current limitations. Early detection and personalized treatment approaches are essential for effective cancer management.

Future research should focus on developing cost-effective and accessible therapeutic strategies to improve global cancer care.

10. ACKNOWLEDGEMENT

The author acknowledges the support of academic resources and institutional guidance during the preparation of this review.

11. Conflict of Interest

The author declares no conflict of interest.

12. REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin., 2021; 71(3): 209–249.
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2023. CA Cancer J Clin., 2023; 73(1): 17–48.
3. Hanahan D. Hallmarks of cancer: New dimensions. Cell, 2022; 185(1): 31–46.
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide. CA Cancer J Clin., 2018; 68(6): 394–424.
5. World Health Organization. World cancer report 2024. Geneva: WHO, 2024.
6. National Cancer Institute. Cancer overview. Bethesda (MD): NCI, 2023.

7. Sharma P, Allison JP. The future of immune checkpoint therapy. Science, 2015; 348(6230): 56–61.
8. Topalian SL, Taube JM, Pardoll DM. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell, 2020; 27(4): 450–461.
9. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science, 2013; 339(6127): 1546–1558.
10. Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet., 2019; 20(2): 71–88.
11. Sawyers CL. Targeted cancer therapy. Nature, 2004; 432(7015): 294–297.
12. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol., 2007; 2(12): 751–760.